Reviewing Momenta Pharmaceuticals Inc. (MNTA)’s and Lannett Company Inc. (NYSE:LCI)’s results

As Drugs – Generic businesses, Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) and Lannett Company Inc. (NYSE:LCI), are affected by compare. This especially applies to their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Momenta Pharmaceuticals Inc. 97.38M 15.23 154.06M -2.01 0.00 Lannett Company Inc. 694.07M 0.53 273.76M -6.99 0.00 Table 1 showcases the gross revenue, earnings per share and valuation of Momenta Pharmaceuticals Inc. and Lannett Company Inc.

Profitability

Table 2 provides us Momenta Pharmaceuticals Inc. and Lannett Company Inc.’s net margins, return on assets and return on equity. Net Margins Return on Equity Return on Assets Momenta Pharmaceuticals Inc. -158.20% -49.7% -37.9% Lannett Company Inc. -39.44% -51.6% -17.9% Volatility and Risk

Momenta Pharmaceuticals Inc. is 128.00% more volatile than Standard & Poor’s 500 because the stock has a beta of 2.28. In other hand, Lannett Company Inc. has beta of 2.02 which is 102.00% more volatile than Standard & Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of Momenta Pharmaceuticals Inc. are 5.4 and 5.4 respectively. Its competitor Lannett Company Inc.’s Current Ratio is 2.9 and its Quick Ratio is 2.1. Momenta Pharmaceuticals Inc. can pay off short and long-term obligations better than Lannett Company Inc.

Analyst Ratings

The Ratings and Recommendations for Momenta Pharmaceuticals Inc. and Lannett Company Inc. are featured in the next table.

$35 is Momenta Pharmaceuticals Inc.’s average price target while its potential upside is 131.79%.

Institutional & Insider Ownership

The shares of both Momenta Pharmaceuticals Inc. and Lannett Company Inc. are owned by institutional investors at 0% and 85.6% respectively. Momenta Pharmaceuticals Inc.’s share held by insiders are 1.8%. Insiders Comparatively, held 6.6% of Lannett Company Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Momenta Pharmaceuticals Inc. 8.95% -10.91% -50.76% -46.36% 4.03% -7.53% Lannett Company Inc. -8.64% 25.35% -4.6% -67.53% -80.78% -76.77% For the past year Momenta Pharmaceuticals Inc. was less bearish than Lannett Company Inc.

Summary

Momenta Pharmaceuticals Inc. beats Lannett Company Inc. on 7 of the 11 factors.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The companyÂ’s complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn’s disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The companyÂ’s novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy; M281, a fully-human monoclonal antibody that blocks the neonatal Fc receptor; and M230, a selective immunomodulator of Fc receptors candidate. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. It also provides its products for various medical indications comprising glaucoma, cholesterol, muscle spasm, migraine, pain management, cardiovascular, antipsychosis, gastrointestinal, urinary, bronchospasms, respiratory, gallstone, congestive heart failure, thyroid deficiency, central nervous system, and gout. In addition, the company manufactures active pharmaceutical ingredients; markets its products under the Diamox, Lipitor, Lioresal, Fioricet, Fiorinal, Lanoxin, Prolixin, MiraLAX, Imdur, Levoxyl/Synthroid, Metadate CD, Concerta, Procardia, Prilosec, Ditropan, Protonix, Imitrex, Brethine, Tussionex, and Actigall brands. Further, it sells pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with JSP, Summit Bioscience LLC, HEC Pharm Group, and Pharma Pass II LLC. Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania.

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *